Boji Medical Technology (300404.SZ): Received government subsidies of 2.89 million yuan.

Boji Medical Technology (stock code 300404) announced on July 3 that its wholly-owned subsidiary, Shenzhen Brightgene Bio-Medical Technology Co., Ltd., has received government subsidy funds related to revenue of 2,890,000.00 yuan recently, accounting for 11.87% of the net income attributable to shareholders of the listed company in the last audited accounting year.

Gelonghui FinanceJul 3 04:03 ET

As Boji Medical TechnologyLtd (SZSE:300404) Jumps 16% This Past Week, Investors May Now Be Noticing the Company's Five-year Earnings Growth

It's nice to see the Boji Medical Technology Co.,Ltd. (SZSE:300404) share price up 16% in a week. But that doesn't change the fact that the returns over the last five years have been less than plea

Simply Wall StJun 20 20:20 ET

Top Buy and Sell Ranking |

Today's top three net buy-in on the Dragon and Tiger List are Boji Medical Technology, Zhonglun New Materials, and Chuanzhi Education.

Gelonghui FinanceJun 20 06:53 ET

Boji Medical Technology rose by the daily limit of 20cm on the stock market, with Foshan Group buying a net of 66.4064 million yuan.

Boji medical technology (300404.SZ) rose by 20 cm today with a turnover of 477 million yuan and a turnover ratio of 21.18%. Dragon and Tiger List data shows that the 'Foshan faction' of fund investors ranks first in buying, with a net purchase of 66.4064 million yuan; the 'leisure and entertainment faction' ranks third in buying, with a net purchase of 15.7825 million yuan; and the 'low position mining faction' ranks fourth in buying, with a net purchase of 11.9872 million yuan. The net buying of the listed seats was 92.8867 million yuan throughout the day.

Gelonghui FinanceJun 20 04:33 ET

Boji Medical Technology (300404.SZ) has the ability to conduct clinical research and development related to synthetic biology.

On June 14, Gelunhui investors asked Boji Medical Technology (300404.SZ) on the investor communication platform, "How many companies has your company cooperated with in synthetic biology projects?" The company replied that the company has the ability to carry out clinical research and development of synthetic biology, and the specific customer information is a commercial secret of the company, which is not convenient to disclose. Please understand.

Gelonghui FinanceJun 14 03:58 ET

Boji Medical Technology (300404.SZ): The company's "amino acid glucosamine hydrochloride and sodium chloride complex compound" in the science and technology park has obtained the approval notice for the listing application of active pharmaceutical ingredi

Boji Medical Technology (300404.SZ) announced on June 13 that its wholly-owned subsidiary, Guangzhou Boji Biomedical Technology Park Co., Ltd. (hereinafter referred to as the "Technology Park Company") applied for and obtained the "Approval Notice for the Application of Listing Chemical Raw Materials for Active Pharmaceutical Ingredients" issued by the National Medical Products Administration for the "sulfate glucosamine chloride sodium complex salt". The "sulfate glucosamine chloride sodium complex salt" can be used to produce related dosage form pharmaceuticals and has anti-inflammatory effects.

Gelonghui FinanceJun 13 06:38 ET